原發漿液性腹膜癌施打bevacizumab 併發壞死性筋膜炎：案例報告與文獻回顧

Necrotizing fasciitis secondary to bevacizumab treatment for primary peritoneal serous carcinoma: a case report and review of literature

血管新生作用對卵巢癌、輸卵管癌、原發性腹膜癌的生長和轉移相當重要，而bevacizumab 是一個阻斷血管內皮生長因子VEGF 受器的合成單株抗體，在治療上的重要性逐年提升。常見之嚴重不良事件包含出血、胃腸道穿孔和動脈血栓栓塞事件，壞死性筋膜炎的發生率相當罕見。然而壞死性筋膜炎乃病程發展迅速又嚴重之感染性疾病，並且在一些文獻中可以在 bevacizumab 治療期間被觀察到。我們在此呈現一位原發漿液性腹膜癌患者施打 bevacizumab 併發致命性壞死性筋膜炎之案例，並回顧現有相關文獻。

Angiogenesis plays a crucial role in progression and metastasis of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor. Therefore, its significance in treating these patients has been raised recently. Serious adverse events with bevacizumab treatment were hemorrhage, gastrointestinal perforation, and arterial thromboembolic events. Though not a common adverse event, necrotizing fasciitis is a severe and fatal soft tissue infection involving the subcutaneous fat and fascia. We hereby present fatal necrotizing fasciitis in a patient during bevacizumab treatment for primary peritoneal serous carcinoma.